Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Shear-dependent platelet aggregation: mechanisms and therapeutic opportunities
Cardiovascular diseases (CVD) are the number one cause of morbidity and death
worldwide. As estimated by the WHO, the global death rate from CVD is 31% wherein, a …
worldwide. As estimated by the WHO, the global death rate from CVD is 31% wherein, a …
Caplacizumab: first global approval
S Duggan - Drugs, 2018 - Springer
Abstract Ablynx, a Sanofi Company, has developed the anti-von Willebrand factor
Nanobody® caplacizumab (Cablivi™) for the treatment of acquired thrombotic …
Nanobody® caplacizumab (Cablivi™) for the treatment of acquired thrombotic …
Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update
PURPOSE To increase awareness, outline strategies, and offer guidance on the
recommended management of immune-related adverse events (irAEs) in patients treated …
recommended management of immune-related adverse events (irAEs) in patients treated …
Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice …
Purpose To increase awareness, outline strategies, and offer guidance on the
recommended management of immune-related adverse events in patients treated with …
recommended management of immune-related adverse events in patients treated with …
Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura
Background In acquired thrombotic thrombocytopenic purpura (TTP), an immune-mediated
deficiency of the von Willebrand factor–cleaving protease ADAMTS13 allows unrestrained …
deficiency of the von Willebrand factor–cleaving protease ADAMTS13 allows unrestrained …
Thrombocytopenia and intracranial venous sinus thrombosis after “COVID-19 vaccine AstraZeneca” exposure
ME Wolf, B Luz, L Niehaus, P Bhogal, H Bäzner… - Journal of clinical …, 2021 - mdpi.com
Background: As of 8 April 2021, a total of 2.9 million people have died with or from the
coronavirus infection causing COVID-19 (Corona Virus Disease 2019). On 29 January 2021 …
coronavirus infection causing COVID-19 (Corona Virus Disease 2019). On 29 January 2021 …
A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP
The anti–von Willebrand factor nanobody caplacizumab was licensed for adults with
immune-mediated thrombotic thrombocytopenic purpura (iTTP) based on prospective …
immune-mediated thrombotic thrombocytopenic purpura (iTTP) based on prospective …
Real-world experience with caplacizumab in the management of acute TTP
T Dutt, RJ Shaw, M Stubbs, J Yong… - Blood, The Journal …, 2021 - ashpublications.org
The cornerstone of life-saving therapy in immune-mediated thrombotic thrombocytopenic
purpura (iTTP) has been plasma exchange (PEX) combined with immunomodulatory …
purpura (iTTP) has been plasma exchange (PEX) combined with immunomodulatory …
Clinical and laboratory diagnosis of TTP: an integrated approach
Thrombotic thrombocytopenia purpura (TTP) is a rare, life-threatening disease with an
incidence of approximately 2 persons per million per year. It is characterized by severe …
incidence of approximately 2 persons per million per year. It is characterized by severe …
COVID-19 and thrombotic microangiopathies
Severe COVID-19 can manifest as multiorgan dysfunction with pulmonary involvement
being the most common and prominent. As more reports emerge in the literature, it appears …
being the most common and prominent. As more reports emerge in the literature, it appears …